L Cöster

3.7k total citations
47 papers, 3.0k citations indexed

About

L Cöster is a scholar working on Cell Biology, Molecular Biology and Rheumatology. According to data from OpenAlex, L Cöster has authored 47 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cell Biology, 25 papers in Molecular Biology and 8 papers in Rheumatology. Recurrent topics in L Cöster's work include Proteoglycans and glycosaminoglycans research (30 papers), Glycosylation and Glycoproteins Research (19 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). L Cöster is often cited by papers focused on Proteoglycans and glycosaminoglycans research (30 papers), Glycosylation and Glycoproteins Research (19 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). L Cöster collaborates with scholars based in Sweden, United States and Austria. L Cöster's co-authors include Anders Malmström, L Å Fransson, I Carlstedt, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Nils Feltelius, Eva Baecklund, Lars Klareskog, Johan Askling and L. Jacobsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

L Cöster

46 papers receiving 2.9k citations

Peers

Countries citing papers authored by L Cöster

Since Specialization

Citations

This map shows the geographic impact of L Cöster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Cöster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Cöster more than expected).

Fields of papers citing papers by L Cöster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Cöster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Cöster. The network helps show where L Cöster may publish in the future.

Co-authorship network of co-authors of L Cöster

This figure shows the co-authorship network connecting the top 25 collaborators of L Cöster. A scholar is included among the top collaborators of L Cöster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Cöster. L Cöster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission 2012 ·Arthritis & Rheumatism ·Katerina Chatzidionysiou, Carl Turesson, Annika Teleman, Ann Knight, Elisabet Lindqvist, Per Larsson, L Cöster, (unknown), Ronald van Vollenhoven, Mikael Heimbürger	12
2	Different types of tissue composition in inflammatory or reparative upper airway disorders 2012 ·Rhinology Journal ·L Cöster, (unknown), (unknown), (unknown), (unknown), J B Watelet	5
3	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial 2009 ·The Lancet ·Ronald van Vollenhoven, Sofia Ernestam, P. Geborek, Ingemar F. Petersson, L Cöster, (unknown), Agneta Zickert, J Theander, (unknown), (unknown), Annika Teleman, (unknown), (unknown), Kristina Forslind, Lotta Ljung, (unknown), Katerina Chatzidionysiou, (unknown), Johan Bratt	224
4	Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment? 2009 ·Arthritis & Rheumatism ·Johan Askling, Ronald van Vollenhoven, Fredrik Granath, Pauline Raaschou, C. Michael Fored, Eva Baecklund, (unknown), Nils Feltelius, L Cöster, Pierre Geborek, L. Jacobsson, Staffan Lindblad, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Lars Klareskog	189
5	Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register 2008 ·Annals of the Rheumatic Diseases ·Johan Askling, Eva Baecklund, Fredrik Granath, P. Geborek, Michael Fored, Carin Backlin, L Bertilsson, L Cöster, L. Jacobsson, Stina Lindblad, J Lysholm, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Ronald van Vollenhoven, Lars Klareskog, Nils Feltelius	197
6	Prevalence of widespread pain and associations with work status: a population study 2008 ·BMC Musculoskeletal Disorders ·Björn Gerdle, Jonas Björk, L Cöster, (unknown), Chris Henriksson, Ann Bengtsson	125
7	The Functions of the Heparan Sulphate Proteoglycans 2007 ·Novartis Foundation symposium ·Lars‐Âke Fransson, Ingemar Carlstedt, L Cöster, Anders Malmström	2
8	TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS). 2006 ·Arthritis & Rheumatism ·Johan Askling, Michael Fored, Lena Brandt, Eva Baecklund, L Bertilsson, L Cöster, P. Geborek, L. Jacobsson, Staffan Lindblad, J Lysholm, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Ronald van Vollenhoven, Nils Feltelius, Lars Klareskog	0
9	TNF-antagonist treatment and risk of hospitalisation for infection. Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS). 2006 ·Arthritis & Rheumatism ·Johan Askling, Michael Fored, Lena Brandt, Eva Baecklund, L Bertilsson, L Cöster, P. Geborek, L. Jacobsson, Staffan Lindblad, J Lysholm, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Ronald van Vollenhoven, Nils Feltelius, Lars Klareskog	1
10	Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA 2005 ·Annals of the Rheumatic Diseases ·Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, L Bertilsson, L Cöster, P. Geborek, L. Jacobsson, Staffan Lindblad, J Lysholm, Solbritt Rantapää‐Dahlqvist, Tore Saxne, (unknown), Lars Klareskog, Nils Feltelius	3
11	Risk of cardiovascular morbidity and mortality following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA 2005 ·Annals of the Rheumatic Diseases ·Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, L Bertilsson, L Cöster, P. Geborek, L. Jacobsson, Staffan Lindblad, J Lysholm, Solbritt Rantapää‐Dahlqvist, Tore Saxne, Nils Feltelius, Lars Klareskog	2
12	Biosynthesis of dermatan sulphate proteoglycans. The effect of β-d-xyloside addition on the polymer-modification process in fibroblast cultures 1991 ·Biochemical Journal ·L Cöster, (unknown), Anders Malmström	27
13	Structure of proteoheparan sulfates from fibroblasts. Confluent and proliferating fibroblasts produce at least three types of proteoheparan sulfates with functionally different core proteins. 1986 ·Journal of Biological Chemistry ·L Cöster, Ingemar Carlstedt, Sally Kendall, Anders Malmström, Artur Schmidtchen, Lars‐Âke Fransson	42
14	Proteoheparan sulfate from human skin fibroblasts. Evidence for self-interaction via the heparan sulfate side chains. 1983 ·Journal of Biological Chemistry ·L Å Fransson, I Carlstedt, L Cöster, Anders Malmström	44
15	Proteoheparan sulfate from human skin fibroblasts. Isolation and structural characterization. 1983 ·Journal of Biological Chemistry ·I Carlstedt, L Cöster, Anders Malmström, L Å Fransson	54
16	The core protein of fibroblast proteoheparan sulphate consists of disulphide-bonded subunits 1983 ·Biochemical Journal ·L Cöster, (unknown), I Carlstedt, L Å Fransson	34
17	Isolation and characterization of dermatan sulphate and heparan sulphate proteoglycans from fibroblast culture 1981 ·Biochemical Journal ·I Carlstedt, L Cöster, Anders Malmström	83
18	Structure and metabolism of sulphated glycosaminoglycans in cultures of human fibroblasts. Structural characteristics of co-polymeric galactosaminoglycans in sequential extracts of fibroblasts during pulse-chase experiments 1979 ·Biochemical Journal ·Ingrid Sjöberg, I Carlstedt, L Cöster, Anders Malmström, L Å Fransson	33
19	Isolation of 35S- and 3H-labelled proteoglycans from cultures of human embryonic skin fibroblasts 1979 ·Biochemical Journal ·L Cöster, I Carlstedt, Anders Malmström	67
20	The copolymeric structure of pig skin dermatan sulphate. Characterization of d-glucuronic acid-containing oligosaccharides isolated after controlled degradation of oxydermatan sulphate 1974 ·Biochemical Journal ·Lars‐Âke Fransson, L Cöster, Anders Malmström, Ingrid Sjöberg	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact